Regenxbio (NASDAQ:RGNX) is set to issue its quarterly earnings data after the market closes on Wednesday, February 27th. Analysts expect the company to announce earnings of ($0.32) per share for the quarter.
Regenxbio stock opened at $46.23 on Thursday. The firm has a market cap of $1.66 billion, a price-to-earnings ratio of -18.87 and a beta of 0.41. Regenxbio has a twelve month low of $26.20 and a twelve month high of $85.10.
In related news, Director Luke M. Beshar sold 20,507 shares of the company’s stock in a transaction on Tuesday, November 27th. The stock was sold at an average price of $65.03, for a total value of $1,333,570.21. Following the transaction, the director now directly owns 1,721 shares of the company’s stock, valued at approximately $111,916.63. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Patrick J. Christmas sold 5,000 shares of the company’s stock in a transaction on Tuesday, December 18th. The shares were sold at an average price of $47.54, for a total value of $237,700.00. Following the completion of the transaction, the senior vice president now directly owns 7,669 shares in the company, valued at $364,584.26. The disclosure for this sale can be found here. In the last quarter, insiders have sold 154,623 shares of company stock valued at $8,296,412. Company insiders own 16.90% of the company’s stock.
RGNX has been the subject of several analyst reports. Chardan Capital reiterated a “buy” rating and set a $127.50 price objective on shares of Regenxbio in a report on Monday, December 17th. Raymond James set a $96.00 price objective on Regenxbio and gave the company a “buy” rating in a report on Thursday, November 8th. Zacks Investment Research upgraded Regenxbio from a “hold” rating to a “buy” rating and set a $78.00 price objective for the company in a report on Wednesday, November 7th. BidaskClub upgraded Regenxbio from a “hold” rating to a “buy” rating in a report on Saturday, November 3rd. Finally, ValuEngine upgraded Regenxbio from a “hold” rating to a “buy” rating in a report on Monday, February 4th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $81.50.
Regenxbio Company Profile
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
Further Reading: What are the Different Types of Leveraged Buyouts?
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.